Cancer research at BESSY II: Binding Mechanisms of Therapeutic Substances Deciphered

The study is displayed on the cover of the journal Chemmedchem.

The study is displayed on the cover of the journal Chemmedchem. © Chemmedchem/VCH Wiley

In tumor cells, the DNA is altered in comparison to normal body cells. How such changes can be prevented or inhibited is an exciting field of research with great relevance for the development of cancer treatments. An interdisciplinary team has now analysed the possible binding mechanisms in certain therapeutic substances from the tetrazole hydrazide group using protein crystallography at BESSY II.

Certain proteins such as human histone demethylases, including the KDM4 protein, play a role in the development of tumour cells. They bind to the DNA and modify it so that the cell can become cancerous. Therapeutic substances that are able to inhibit or even reverse such changes are of particular interest.

Biochemist Prof. Dr. Udo Heinemann from the Max Delbrück Centre in Berlin-Buch is investigating such processes. In cooperation with chemists led by Prof. Dr. Andreas Link from the University of Greifswald and the team led by Dr. Manfred Weiss at the HZB, he has now investigated how and where certain therapeutic substances from the tetrazole hydrazide group dock to these protein molecules and thus inhibit their harmful effect.

KDM4 protein crystals analysed

Link initially produced variations of tetrazole hydrazide substances. For structural analysis, crystals had to be grown from KDM4 proteins - a difficult task that Dr. Piotr Malecki and Manfred Weiss had taken on at the HZB. The KDM4 protein crystals were then soaked in a specific substance before being analyzed with strong X-rays on the MX beamlines of BESSY II. A refined analysis showed not only the three-dimensional architecture of the KDM4 protein, but also exactly where the active substances had docked to the KDM4 molecule.

"This class of substances has not yet been structurally investigated," explains Manfred Weiss.  And Udo Heinemann from the MDC explains: "We will now evaluate where there are opportunities to dock even stronger within the 3D structure of the KDM4. Then we might also be able to develop drugs that inhibit the KDM4 even more and thus have the potential to become a therapeutic."

arö

  • Copy link

You might also be interested in

  • Battery research: visualisation of aging processes operando
    Science Highlight
    29.04.2025
    Battery research: visualisation of aging processes operando
    Lithium button cells with electrodes made of nickel-manganese-cobalt oxides (NMC) are very powerful. Unfortunately, their capacity decreases over time. Now, for the first time, a team has used a non-destructive method to observe how the elemental composition of the individual layers in a button cell changes during charging cycles. The study, now published in the journal Small, involved teams from the Physikalisch-Technische Bundesanstalt (PTB), the University of Münster, researchers from the SyncLab research group at HZB and the BLiX laboratory at the Technical University of Berlin. Measurements were carried out in the BLiX laboratory and at the BESSY II synchrotron radiation source.
  • New instrument at BESSY II: The OÆSE endstation in EMIL
    Science Highlight
    23.04.2025
    New instrument at BESSY II: The OÆSE endstation in EMIL
    A new instrument is now available at BESSY II for investigating catalyst materials, battery electrodes and other energy devices under operating conditions: the Operando Absorption and Emission Spectroscopy on EMIL (OÆSE) endstation in the Energy Materials In-situ Laboratory Berlin (EMIL). A team led by Raul Garcia-Diez and Marcus Bär showcases the instrument’s capabilities via a proof-of-concept study on electrodeposited copper.
  • Green hydrogen: A cage structured material transforms into a performant catalyst
    Science Highlight
    17.04.2025
    Green hydrogen: A cage structured material transforms into a performant catalyst
    Clathrates are characterised by a complex cage structure that provides space for guest ions too. Now, for the first time, a team has investigated the suitability of clathrates as catalysts for electrolytic hydrogen production with impressive results: the clathrate sample was even more efficient and robust than currently used nickel-based catalysts. They also found a reason for this enhanced performance. Measurements at BESSY II showed that the clathrates undergo structural changes during the catalytic reaction: the three-dimensional cage structure decays into ultra-thin nanosheets that allow maximum contact with active catalytic centres. The study has been published in the journal ‘Angewandte Chemie’.